Biotech News
Related news
NERVMinerva Neuroscience2026-10-29 11:00 EST
Minerva Neurosciences to Participate in 2026 Jefferies Global Healthcare Conference in London
CGTXCognition Therapeutics2026-11-09 12:30 EST
Cognition Therapeutics Invited to Participate in 2026 Jefferies Global Healthcare Conference
NBIXNeurocrine Biosciences2026-11-10 21:01 EST
Neurocrine Biosciences to Present at the 2026 Jefferies Global Healthcare Conference
GANXGain Therapeutics2026-09-17 11:00 EST
Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference
TEVATeva Pharmaceutical Industries2026-11-20 21:30 EST
Teva to Present at the 9th Annual Evercore Healthcare Conference, the Piper Sandler 38th Annual Healthcare Conference and Citi’s 2026 Global Healthcare Conference
HRMYHarmony Biosciences2026-11-19 13:05 EST
Harmony Biosciences to Participate in Upcoming Investor Conferences
TNXPTonix Pharmaceuticals2026-11-04 12:00 EST
Tonix Pharmaceuticals to Present at Guggenheim’s 3rd Annual Healthcare Innovation Conference
RVPHReviva Pharmaceuticals2026-09-22 12:00 EST
Reviva to Participate in the Lytham Partners Fall 2026 Investor Conference
HRMYHarmony Biosciences2026-10-01 12:05 EST
Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days
ECORelectroCore2026-09-10 12:00 EST
electroCore to Participate at H.C. Wainwright Global Investment Conference
Supernus
CNS Commercial Portfolio Supernus Pharmaceuticals develops and commercializes treatments for central nervous system disorders. Its marketed portfolio spans attention-deficit hyperactivity disorder, Parkinson’s disease, postpartum depression, epilepsy, migraine, cervical dystonia and chronic sialorrhea. Growth Products The company’s...
Recent company news
SUPNSupernus2026-11-10 13:30 EST
Supernus, Inc. to Participate in the 2026 Jefferies Global Healthcare Conference in London
SUPNSupernus2026-11-02 14:18 EST
Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader
SUPNSupernus2026-10-29 20:05 EST
Supernus Announces Third Quarter 2026 Financial Results
SUPNSupernus2026-10-28 12:30 EST
Chloe Kim Is Changing the Conversation Around ADHD in Women with Qelbree® for ‘Ms. Represented’ Campaign
SUPNSupernus2026-10-21 23:45 EST
Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)
Stock data
- Close
- 28.35 USD
- Market cap
- 2.56B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States
